Company intelligence / Profile preview

ExoCan Healthcare Technologies

Pune, India
Ownership
Private
Employees
~25
Development stage
Other
01

Overview

ExoCan is developing exosome-based therapeutics and diagnostics for cancer and regenerative medicine. The company has multiple technology platforms including a proprietary exosome discovery platform for clinical-grade production and DerPileXO for active cargo loading into exosomes.

Therapeutic areas
OncologyDermatology
Modalities
Exosome-based therapySmall moleculeNucleic acid therapy
Industry
Biotech
02

Drug pipeline

3 assets

EC-101

Preclinical

2 more assets in the full pipeline.

Request access →
03

Partnerships

AKS Clinic

Beyond the preview

Go deeper on ExoCan Healthcare Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoCan Healthcare Technologies.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call